CentonzeFG, ReitererV, NalbachK, et al.LTK is an ER-resident receptor tyrosine kinase that regulates secretion. J Cell Biol, 2019; 218(8):2470–2480; doi: 10.1083/jcb.201903068.
2.
NoackJ, BernasconiR, MolinariM. How viruses hijack the ERAD tuning machinery. J Virol, 2014; 88(18):10272–10275; doi: 10.1128/JVI.00801-14.
3.
ErikssonA, ÖsterroosA, HassanS, et al.Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia. Blood Cancer J, 2015; 5(4):e307; doi: 10.1038/bcj.2015.31.
4.
ErikssonA, ChantziE, FryknäsM, et al.Towards repositioning of quinacrine for treatment of acute myeloid leukemia—Promising synergies and in vivo effects. Leuk Res, 2017; 63:41–46; doi: 10.1016/j.leukres.2017.10.012.
5.
JohnstonBP, McCormickC. Herpesviruses and the unfolded protein response. Viruses, 2020; 12(1):17; doi: 10.3390/v12010017.
6.
KolbPS, AyaubEA, ZhouW, et al.The therapeutic effects of 4-phenylbutyric acid in maintaining proteostasis. Int J Biochem Cell Biol, 2015; 61:45–52; doi: 10.1016/j.biocel.2015.01.015.
7.
YeJ. Roles of regulated intramembrane proteolysis in virus infection and antiviral immunity. Biochim Biophys Acta, 2013; 1828(12):2926–2932; doi: 10.1016/j.bbamem.2013.05.005.
8.
WiedemarN, HauserDA, MäserP. 100 years of suramin. Antimicrob Agents Chemother, 2020; 64(3):e01168-19; doi: 10.1128/AAC.01168-19.
9.
FischerW, KrugelU. P2Y receptors: Focus on structural, pharmacological and functional aspects in the brain. Curr Med Chem, 2007; 14(23):2429–2455; doi: 10.2174/092986707782023695.
10.
GhebremariamYT, CookeJP, GerhartW, et al.Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis. J Transl Med, 2015; 13(1):249; doi: 10.1186/s12967-015-0614-x.
11.
LeeJS, CollardHR, AnstromKJ, et al.Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: An analysis of data from three randomised controlled trials. Lancet Respir Med, 2013; 1(5):369–376; doi: 10.1016/S2213-2600(13)70105-X.
12.
TranT, AssayagD, ErnstP, et al.Effectiveness of proton pump inhibitors in idiopathic pulmonary fibrosis: A population-based cohort study. CHEST, 2021; 159(2):673–682; doi: 10.1016/j.chest.2020.08.2080.
13.
HashiokaS. Antidepressants and neuroinflammation: Can antidepressants calm glial rage down?. Mini Rev Med Chem, 2011; 11(7):555–564.
14.
PandurangiAK, BuckleyPF. Inflammation, antipsychotic drugs, and evidence for effectiveness of anti-inflammatory agents in schizophrenia. Curr Top Behav Neurosci, 2020; 44:227–244; doi: 10.1007/7854_2019_91.
GuoX, QiX, FanP, et al.Effect of ondansetron on reducing ICU mortality in patients with acute kidney injury. Sci Rep, 2021; 11(1):19409; doi: 10.1038/s41598-021-98734-x.
17.
TaoL, ZhouS, ChangP, et al.Effects of ondansetron use on outcomes of acute kidney injury in critically ill patients: An analysis based on the MIMIC-IV database. J Crit Care, 2021; 66:117–122; doi: 10.1016/j.jcrc.2021.07.015.
18.
XiongD, XiongC. Early postoperative ondansetron exposure is associated with reduced 90-day mortality in patients undergoing cardiac surgery. Front Surg, 2022; 9:885137; doi: 10.3389/fsurg.2022.885137.
19.
ThalDM, HomanKT, ChenJ, et al.Paroxetine is a direct inhibitor of G protein-coupled receptor kinase 2 and increases myocardial contractility. ACS Chem Biol, 2012; 7(11):1830–1839; doi: 10.1021/cb3003013.
20.
SunX, ZhouM, WenG, et al.Paroxetine attenuates cardiac hypertrophy via blocking GRK2 and ADRB1 interaction in hypertension. J Am Heart Assoc, 2021; 10(1):e016364; doi: 10.1161/JAHA.120.016364.
21.
KowalskaM, NowaczykJ, Fijałkowski Ł, et al. Paroxetine—Overview of the molecular mechanisms of action. Int J Mol Sci, 2021; 22(4):1662; doi: 10.3390/ijms22041662.
22.
SainA, BansalH, PattabiramanK, et al.Present and future scope of recombinant parathyroid hormone therapy in orthopaedics. J Clin Orthop Trauma, 2021; 17:54–58; doi: 10.1016/j.jcot.2021.01.019.
23.
CarlsonEL, KaruppagounderV, PinamontWJ, et al.Paroxetine-mediated GRK2 inhibition is a disease-modifying treatment for osteoarthritis. Sci Transl Med, 2021; 13(580):eaau8491; doi: 10.1126/scitranslmed.aau8491.
24.
FuF, HuS, DeleoJ, et al.Long-term islet graft survival in streptozotocin- and autoimmune-induced diabetes models by immunosuppressive and potential insulinotropic agent Fty720. Transplantation, 2002; 73(9):1425–1430.
25.
BergmannC, Guay-WoodfordLM, HarrisPC, et al.Polycystic kidney disease. Nat Rev Dis Primer, 2018; 4(1):1–24; doi: 10.1038/s41572-018-0047-y.
26.
GueriniAE, TriggianiL, MaddaloM, et al.Mebendazole as a candidate for drug repurposing in oncology: An extensive review of current literature. Cancers, 2019; 11(9):1284; doi: 10.3390/cancers11091284.
27.
BlomK, SenkowskiW, JarviusM, et al.The anticancer effect of mebendazole may be due to M1 monocyte/macrophage activation via ERK1/2 and TLR8-dependent inflammasome activation. Immunopharmacol Immunotoxicol, 2017; 39(4):199–210; doi: 10.1080/08923973.2017.1320671.
SukhikhGT, ZiganshinaMM, NizyaevaNV, et al.Differences of glycocalyx composition in the structural elements of placenta in preeclampsia. Placenta, 2016; 43:69–76; doi: 10.1016/j.placenta.2016.05.002.
RupniakNMJ, KramerMS. NK1 receptor antagonists for depression: Why a validated concept was abandoned. J Affect Disord, 2017; 223:121–125; doi: 10.1016/j.jad.2017.07.042.
32.
MuñozM, CoveñasR. The neurokinin-1 receptor antagonist aprepitant: An intelligent bullet against cancer?. Cancers, 2020; 12(9):2682; doi: 10.3390/cancers12092682.
33.
CovenasR, MunozM. Cancer progression and substance P. Histol Histopathol, 2014; 29(7):881–890; doi: 10.1467/0/HH-29.881.
34.
BadrD, KurbanM, AbbasO. Metformin in dermatology: An overview. J Eur Acad Dermatol Venereol, 2013; 27(11):1329–1335; doi: 10.1111/jdv.12116.
35.
LiY, YangL, WangY, et al.Exploring metformin as a candidate drug for rosacea through network pharmacology and experimental validation. Pharmacol Res, 2021; 174:105971; doi: 10.1016/j.phrs.2021.105971.
36.
El-RidyMS, YehiaSA, ElsayedI, et al.Metformin hydrochloride and wound healing: From nanoformulation to pharmacological evaluation. J Liposome Res, 2019; 29(4):343–356; doi: 10.1080/08982104.2018.1556291.
37.
ChenX-F, TangW, LinW-D, et al.Receptor for advanced glycation end as drug targets in diabetes-induced skin lesion. Am J Transl Res, 2017; 9(2):330–342.
38.
RapanelliM, PittengerC. Histamine and histamine receptors in tourette syndrome and other neuropsychiatric conditions. Neuropharmacology, 2016; 106:85–90; doi: 10.1016/j.neuropharm.2015.08.019.
39.
ZhangX-Y, PengS-Y, ShenL-P, et al. Targeting presynaptic H3 heteroreceptor in nucleus accumbens to improve anxiety and obsessive-compulsive-like behaviors. Proc Natl Acad Sci U S A 2020;117(50):32155–32164; doi: 10.1073/pnas.2008456117.
40.
MalaraM, LutzA-K, IncearapB, et al.SHANK3 deficiency leads to myelin defects in the central and peripheral nervous system. Cell Mol Life Sci, 2022; 79(7):371; doi: 10.1007/s00018-022-04400-4.
41.
QinL, MaK, WangZ-J, et al.Social deficits in Shank3-deficient mouse models of autism are rescued by histone deacetylase (HDAC) inhibition. Nat Neurosci, 2018; 21(4):564–575; doi: 10.1038/s41593-018-0110-8.
42.
LiuJ, DupreeJL, GaciasM, et al.Clemastine enhances myelination in the prefrontal cortex and rescues behavioral changes in socially isolated mice. J Neurosci, 2016; 36(3):957–962; doi: 10.1523/JNEUROSCI.3608-15.2016.
43.
YaoK, NagashimaK, MikiH. Pharmacological, pharmacokinetic, and clinical properties of benidipine hydrochloride, a novel, long-acting calcium channel blocker. J Pharmacol Sci, 2006; 100(4):243–261; doi: 10.1254/jphs.DTJ05001X.
44.
AkizukiO, InayoshiA, KitayamaT, et al.Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R. Eur J Pharmacol, 2008; 584(2):424–434; doi: 10.1016/j.ejphar.2008.02.001.
45.
InayoshiA, SugimotoY, FunahashiJ, et al.Mechanism underlying the block of human Cav3.2 T-Type Ca2+ channels by benidipine, a dihydropyridine Ca2+ channel blocker. Life Sci, 2011; 88(19):898–907; doi: 10.1016/j.lfs.2011.03.019.
46.
PowellKL, CainSM, SnutchTP, et al.Low threshold T-type calcium channels as targets for novel epilepsy treatments. Br J Clin Pharmacol, 2014; 77(5):729–739; doi: 10.1111/bcp.12205.
47.
KoçakMN, ArslanR, AlbayrakA, et al.An antihypertensive agent benidipine is an effective neuroprotective and antiepileptic agent: An experimental rat study. Neurol Res, 2021; 43(12):1069–1080; doi: 10.1080/01616412.2021.1949685.
DingL, JiangP, XuX, et al.T-type calcium channels blockers inhibit HSV-2 infection at the late stage of genome replication. Eur J Pharmacol, 2021; 892:173782; doi: 10.1016/j.ejphar.2020.173782.
